Paris – 28.05.2026: In a significant development for obesity treatment in France, Health Minister Stéphanie Rist announced today that the drugs Wegovy and Mounjaro are now reimbursed. This decision marks a key milestone in the fight against obesity, which affects more than eight million people in France.
Wegovy, a drug from the Danish pharmaceutical group Novo Nordisk, was not reimbursed in France since its launch in October 2024 and cost patients between 274 and 365 euros per month. With the new reimbursement policy, the price for the first three doses is set at 146.91 euros per month, representing significant savings for patients.
The decision to reimburse Wegovy and Mounjaro was made after intense negotiations between the French Ministry of Health and the manufacturers. These discussions focused on setting a fair price and determining the reimbursement rate by mandatory health insurance. Although the exact details of the agreement have not yet been published, the reimbursement is expected to take effect in the second half of 2026.
The reimbursement of these drugs is expected to have a significant impact on obesity treatment in France. Experts estimate that the annual cost of reimbursement will be around 100 million euros. This investment is considered necessary to manage the increasing healthcare expenses related to obesity and to improve the quality of life for the affected patients.
Novo Nordisk welcomed the decision of the French government and emphasized that the reimbursement of Wegovy represents a major advance in the fight against obesity. The company also announced that it would reduce the price of Wegovy in France to 146.91 euros per month for the first three doses, to further improve access to the medication.
The introduction of reimbursement for Wegovy and Mounjaro is considered by health experts as a step in the right direction to improve obesity treatment in France. However, it is emphasized that a comprehensive strategy is necessary, including not only drug therapies but also prevention measures and an improvement in the population’s eating habits.
The French government plans to widely inform the public in the coming weeks about the details of the reimbursement and the prescribing conditions for Wegovy and Mounjaro. Patients interested in treatment with these drugs are encouraged to consult their general practitioner or a specialist to obtain more information and discuss the therapeutic option that suits them best.
The decision to reimburse Wegovy and Mounjaro in France is considered an important step in the fight against obesity and could serve as a model for other European countries facing similar challenges. It remains to be seen how this decision will influence the prevalence of obesity and the associated healthcare costs in France.
Dieser Artikel wurde mit Hilfe künstlicher Intelligenz erstellt.